September 21, 2018
Two major market events have the potential to send equity volumes higher will strike on Friday.
The first is the quarterly event known as “quadruple witching” -- when futures and options on indexes and individual stocks expire. That generally results in some of the biggest trading days of the year. But today brings a wild card -- the largest revision to the Global Industry Classification Standard (GICS) since 1999.
Pre-open indications: 1 BUY, 1 SELL with news, 2 HOLDS with financings, 7 overbought and 1 oversold
Financing: Fate Therapeutics (FATE) priced their 9,250,260 share offering at $13.50 for an aggregate of approximately $125 million. FATE had closed at $14.03 (+$0.67 or +5.01%)
What is fair game as defined by legitimate equities to trade?
RMi provides a pre-market synopsis for the U.S. trading day.
September 21, 2018
FATE had closed at $14.03 (+$0.67 or +5.01%) and was down in the pre-market -$0.63 or -4.49%
FATE had 53.42 M shares outstanding, a float of 44.68 M and a 52 week change of +224.27% with a cash position of $78.02 M and $14.85 M in debt on the books
A good move after a market high and collaboration news with ONO Pharmaceuticals
September 21, 2018
The quadruple witch swept the sector’s floor; out went many of the new highs especially in the Crisprs
As I had stated, “buckle-up” while many of my past week’s “predictions” have come full circle!
Pre-open indications: 9 HITs and 4 MISS
Out and about: The Crisprs; NTLA (-$4.73 or -15.01%), CRSP (-$4.50 or -9.19%) and EDIT (-$2.47 or -7.58%) were swept in the dust of CRSP’s financing as one analyst calls it – “crispy and overcooked”
Who is putting the facts into evidence for the metrics to "speak" to individual investors and which broker, trader, fund or I-Bank is keeping you notified of the sector and market fluctuations?
RMi’s daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.
September 11, 2018
Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies Thirty-six (36) LPS, four (4) net income and two (2) delayed or incomplete - Intrexon (XON) and MiMedx (MDXG) ... so far of 45 covered companies The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
September 5, 2018
HSGX drops -$1.71 or -61.73% (from yesterday’s close of $2.77) as VCEL gains +$1.85 or +15.88% A “gift” for VCEL, MACI and ... another offering?
August 17, 2018
I maintain as a short-term trading vehicle as there is more historical upside to “eat” through! Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates; .... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%)
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
September 21, 2018
RegMed Investors’ (RMi) closing bell: another I told you so
September 21, 2018
Fate Therapeutics (FATE) priced their 9,250,260 share offering at $13.50 for an aggregate of approximately $125 million
September 21, 2018
RegMed Investors’ (RMi) pre-open: buckle up
September 21, 2018
RegMed Investors’ (RMi) pre-open: buckle up
September 20, 2018
CRISPR Therapeutics (CRSP) prices 4.210526 M shares at $47.50, a $200 M offering with a $30 M underwriting option
September 20, 2018
RegMed Investors’ (RMi) closing bell: tick, tick and a top
September 20, 2018
RegMed Investors’ (RMi) pre-open: is this sector trend your friend?
September 19, 2018
RegMed Investors’ (RMi) closing bell: an erratic pricing open, moderated at the mid-day and closed to the upside
September 19, 2018
RegMed Investors’ (RMi) pre-open: loading-up on spiking stocks could be detrimental to your portfolio
September 18, 2018
RegMed Investors’ (RMi) closing bell: a strong dose of value
September 18, 2018
RegMed Investors’ (RMi) pre-open: another sector crash too far
September 17, 2018
RegMed Investors’ (RMi) closing bell: optimism about pricing after a drubbing
September 17, 2018
RegMed Investors’ (RMi) pre-open: volume has been turned down
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
